FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
26 July 2024
Video
Ten Minute Interview: Art Ownership
Brian Lucareli, director of Foley Private Client Services and co-chair of Foley’s Family Offices group, sits down with Lindsey Birch, associate and member of our Intellectual Property practice group, for a 10-minute interview to discuss art ownership.
26 July 2024
Foley In Fashion
Passing the Torch: Technology in the Opening Ceremony Fashion at the Paris Olympics
With the 2024 Olympic Games set in Paris, France, one of the world’s fashion capitals, athletics and aesthetics collide to take center stage at the much-anticipated opening ceremony.
25 July 2024
Foley In Fashion
SHEIN’s $1.9 Million Data Breach: A Cautionary Tale for Online Fashion Brands
The New York Attorney General fined fast-fashion company, Shein Distribution Corporation, $1.9 million for failing to properly handle a data breach in late 2022.